PharmaOnco™ Ralimetinib Mesylate

CAT#: ITS-0622-YT324
Product Type: Small Molecules
Species: Human, Mouse, Rat, Non-Human Primate, Other
Product Overview
Ralimetinib Mesylate (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β (IC₅₀ = 5.3 and 3.2 nM, respectively) with anti-inflammatory and anti-neoplastic activities. It selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc. PharmaOnco™ Ralimetinib Mesylate is supplied as the dimesylate salt of the molecule.
Applications
Cell Expansion, Maintenance
Size
1 mg
Chemical Name
5-[2-(1,1-dimethylethyl)-4-(4-fluorophenyl)-1H-imidazol-5-yl]-3-(2,2-dimethylpropyl)-3H-imidazo[4,5-b]pyridin2-amine, dimethanesulfonate
Cell Type
Cancer Cells and Cell Lines, Hematopoietic Stem and Progenitor Cells
Species
Human, Mouse, Rat, Non-Human Primate, Other
Pathway
p38 MAPK
Target
p38 MAPK α/β
Subtype
p38 MAPK Inhibitor
Area of Interest
Immunology
Limitation
Restrictions for research use only. Intended for use by laboratory professionals.
Shelf Life
Stable as supplied until expiry date on label.
Storage
Store at -20°C
Molecular Weight
612.7 g/mol
Format
Solid
For Research Use Only | Not For Clinical Use
Online Inquiry